COMP <GO>
GEHC vs ABBV // FREE CASH FLOW YIELD
GE HealthCare Technologies Inc. Common Stock (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: GEHC 6
— ABBV 7
▲ FREE CASH FLOW YIELD LEADER: GEHC
LAST: $76.57 (+0.20%) • MKT CAP: $34.55B
fcf-yield
4.19%
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
fcf-yield
3.47%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GEHC VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GEHC | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 40.00% | 70.20% | -30.20 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 14.20% | 29.00% | -14.80 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 11.1x | 33.3x | -22.20 | GEHC | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | 4.19% | 3.47% | +0.72 | GEHC | /fcf-yield <GO> |
| Operating Margin | 13.40% | 24.60% | -11.20 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 10.10% | 6.90% | +3.20 | GEHC | /net-margins <GO> |
| Revenue Growth (YoY) | 4.80% | 8.60% | -3.80 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.19% | 2.27% | -2.08 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.90 | 5.33 | -3.43 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | GEHC | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.40% | 7.40% | 0.00 | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 74.1 | 72.8 | +1.32 | GEHC | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.15 | 1.15 | 0.00 | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 15.4x | 113.1x | -97.70 | GEHC | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $34.55B | $513.86B | -$479.31B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GEHC REV | ABBV REV | GEHC GROSS % | ABBV GROSS % | GEHC FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $20.63B | $61.16B | 40.0% | 70.2% | $1.41B | $17.82B |
| FY 2024 | $19.67B | $56.33B | 41.7% | 70.0% | $1.35B | $17.83B |
| FY 2023 | $19.55B | $54.32B | 44.0% | 44.0% | $876.3M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GEHC // BETA 1.15
ABBV // BETA 1.15